Justin Taylor, M.D. (IMAGE)
Caption
“The main finding was that a new BTK mutation, first described by us in 2022, causes resistance in patients treated with BTK degraders,” said Justin Taylor, M.D., co-author of the study and physician-scientist at Sylvester. “The BTK A428D mutation has emerged as a resistance mechanism to these BTK degraders in clinical trials, and those in development, plus all approved BTK inhibitors.”
Credit
Sylvester Comprehensive Cancer Center
Usage Restrictions
Use with attribution
License
Original content